Menu
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals.